Levi & Korsinsky notifies investors that it has commenced an investigation into Alector, Inc. (NASDAQ: ALEC) concerning potential violations of the federal securities laws.
On October 22, 2025, Alector announced results from its Phase 2 INFRONT-3 clinical trial evaluating latozinemab (AL001) in patients with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). The company reported that “latozinemab did not demonstrate a clinical benefit” for slowing FTD-GRN progression in its 96-week double-blind trial. Following this news, ALEC’s stock price fell over 52% to open at $1.54 per share.
If you suffered a loss on your Alector, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





